{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.0","upperLimit":"43.0","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"}],"units":"Participants"}],"description":"Percentage of participants with CR plus CRh (CR, Molecular CR \\[CRm\\], Cytogenetic CR \\[CRc\\], CRh) is re-ported. CR is defined as bone marrow blasts less than (\\<) 5 percent (%) (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, absolute neutrophil count (ANC) greater than or equal to (\\>=) 1000/μL, platelet count \\>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is defined as CR with unde-tectable IDH1m minimal residual disease (MRD) and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \\>50 × 10\\^9/L and ANC \\> 0.5 × 10\\^9/L).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 1; FT-2102 (Single Agent)"}],"paramType":"NUMBER","populationDescription":"Efficacy evaluable analysis set included all participants in Phase 2, Cohort 1 with confirmed IDH1-R132 who have received the first dose of FT-2102 180 days or more prior to the analysis cutoff date. This outcome measure is applicable only for Cohort 1.","reportingStatus":"POSTED","timeFrame":"Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)","title":"Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}